Rusfertide effectively maintained hematocrit control below 45% and reduced phlebotomy eligibility in PV patients through 52 weeks. Patients switching from placebo to rusfertide achieved rapid and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results